Search

Displaying results 4151 - 4160 of 10000 in total
  1. Drug

    Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen

    go.drugbank.com/drugs/DB14394
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  2. Drug

    Influenza A virus A/Texas/50/2012 X-223A (H3N2) hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB14399
    Approved

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  3. Drug

    Influenza B virus B/Massachusetts/2/2012 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB14400
    Approved

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  4. Drug

    Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB14403
    Approved

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  5. Drug

    Influenza A virus A/Christchurch/16/2010 NIB-74XP (H1N1) hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14419
    Approved

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  6. Drug

    Influenza B virus B/Utah/9/2014 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB14421
    Approved

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  7. Drug

    Influenza A virus A/Hong Kong/4801/2014 X-263B (H3N2) hemagglutinin antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB14424
    Approved

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  8. Drug

    Influenza A virus A/Singapore/gp1908/2015 IVR-180 (H1N1) hemagglutinin antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB14431
    Approved

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  9. Drug

    Influenza A virus A/Singapore/gp1908/2015 IVR-180 (H1N1) hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14432
    Approved

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  10. Drug

    Influenza A virus A/Singapore/gp1908/2015 IVR-180 (H1N1) hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB14433
    Approved

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen